Dear Editor,Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease in which proliferation of massive cells from the myeloid lineage occurs. The Philadelphia (Ph) chromosome is a CML genetic abnormality characteristic, and results from a reciprocal translocation between the long arms of chromosomes 9 and 22, generating a BCR‐ABL oncoprotein with constitutively activated tyrosine kinase activity [Druker et al., ].The development of tyrosine kinase inhibitors (TKIs) has revolutionized CML treatment because they are able to block cell proliferation of malignant clones by interfering with the interaction between a BCR‐ABL1 oncoprotein and adenosine triphosphate (ATP) [Jabbour and Kantarjian, ].Despite the success of TKIs for CML treatment, these drugs need to be monitored because of the occurrence of adverse events. Reports in the literature have described special situations with regard to TKI treatment safety. Some authors have reported the occurrence of cytogenetic changes in Ph– cells during treatment with imatinib and the presence of secondary disease that resembled myelodysplastic syndrome or acute myeloid leukemia has been observed in some patients [Medina et al., ; Loriaux and Deininger, ; Jabbour et al., ]. In another study, it was observed that stem cells from normal donors acquired post‐transplant cytogenetic changes during therapy with
Environmental and Molecular Mutagenesis – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera